| Id: | acc2110 |
| Group: | 2sens |
| Protein: | MYC |
| Gene Symbol: | MYC |
| Protein Id: | P01106 |
| Protein Name: | MYC_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr58 |
| Site Sequence: | QQQQSELQPPAPSEDIWKKFE |
| Disease Category: | Cancer |
| Disease: | Prostate Cancer |
| Disease Subtype: | |
| Disease Cellline: | MycCaP |
| Disease Info: | |
| Drug: | anti-PD1 immunotherapy |
| Drug Info: | - |
| Effect: | sensitize |
| Effect Info: | "MYCi361 inhibited tumor growth in mice, increased the infiltration of tumor immune cells, upregulated PD-L1 on tumors, and made tumors sensitive to anti-PD1 immunotherapy." |
| Note: | Non-conventional drugs |
| Score: | 4.5 |
| Pubmed(PMID): | 31679823 |
| Sentence Index: | 31679823_3-4 |
| Sentence: | "The compounds enhance MYC phosphorylation on threonine-58, consequently increasing proteasome-mediated MYC degradation. The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy." |
Sequence & Structure:
MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MYC-Ser176 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser362 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.131 | ||||
| COAD | -0.769 | ||||
| HGSC | -0.362 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser363 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser76 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.857 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.134 | ||||
| GBM | 1.257 | ||||
| HNSC | 0.736 | ||||
| LUAD | -0.146 | ||||
| LUSC | -0.348 | ||||
| non_ccRCC | |||||
| PDAC | -0.678 | ||||
| UCEC | 0.902 | ||||
| MYC-Ser77 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser78 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser79 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYC-Ser85 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.711 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.963 | ||||
| GBM | 1.12 | ||||
| HNSC | 0.547 | ||||
| LUAD | 0.557 | ||||
| LUSC | 0.268 | ||||
| non_ccRCC | |||||
| PDAC | -1.693 | ||||
| UCEC | 0.875 | ||||
| MYC-Thr72 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.784 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.003 | ||||
| GBM | 0.708 | ||||
| HNSC | 0.829 | ||||
| LUAD | 0.713 | ||||
| LUSC | -0.945 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.475 | ||||
| MYC-Thr73 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser1624 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.752 | ||||
| HGSC | 1.135 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.383 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser178 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.144 | ||||
| HGSC | |||||
| ccRCC | -0.849 | ||||
| GBM | 1.719 | ||||
| HNSC | -0.67 | ||||
| LUAD | -0.863 | ||||
| LUSC | -0.269 | ||||
| non_ccRCC | 1.225 | ||||
| PDAC | -0.948 | ||||
| UCEC | 0.798 | ||||
| MYCBP2-Ser181 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.869 | ||||
| COAD | -0.244 | ||||
| HGSC | |||||
| ccRCC | 0.166 | ||||
| GBM | -0.535 | ||||
| HNSC | -0.377 | ||||
| LUAD | -0.506 | ||||
| LUSC | 0.606 | ||||
| non_ccRCC | 2.493 | ||||
| PDAC | -0.926 | ||||
| UCEC | 0.191 | ||||
| MYCBP2-Ser183 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.876 | ||||
| COAD | -0.193 | ||||
| HGSC | |||||
| ccRCC | 0.16 | ||||
| GBM | -0.541 | ||||
| HNSC | -0.383 | ||||
| LUAD | -0.512 | ||||
| LUSC | 0.602 | ||||
| non_ccRCC | 2.49 | ||||
| PDAC | -0.933 | ||||
| UCEC | 0.186 | ||||
| MYCBP2-Ser2061 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MYCBP2-Ser2319 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.268 | ||||
| COAD | 0.094 | ||||
| HGSC | 2.875 | ||||
| ccRCC | -0.158 | ||||
| GBM | -0.15 | ||||
| HNSC | -0.451 | ||||
| LUAD | -0.041 | ||||
| LUSC | -0.033 | ||||
| non_ccRCC | -0.994 | ||||
| PDAC | -0.308 | ||||
| UCEC | -0.564 | ||||
| MYCBP2-Ser2353 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 2.183 | ||||
| HGSC | |||||
| ccRCC | 0.093 | ||||
| GBM | -1.324 | ||||
| HNSC | 0.006 | ||||
| LUAD | -0.034 | ||||
| LUSC | -1 | ||||
| non_ccRCC | -0.531 | ||||
| PDAC | 0.237 | ||||
| UCEC | 0.37 | ||||
| MYCBP2-Ser2681 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.72 | ||||
| ccRCC | |||||
| GBM | -0.996 | ||||
| HNSC | 0.762 | ||||
| LUAD | 0.953 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2687 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.694 | ||||
| HGSC | -1.476 | ||||
| ccRCC | 0.435 | ||||
| GBM | 0.479 | ||||
| HNSC | 0.156 | ||||
| LUAD | -0.626 | ||||
| LUSC | 1.243 | ||||
| non_ccRCC | -0.296 | ||||
| PDAC | 1.725 | ||||
| UCEC | -0.947 | ||||
| MYCBP2-Ser2741 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.209 | ||||
| GBM | |||||
| HNSC | -0.62 | ||||
| LUAD | -1.073 | ||||
| LUSC | |||||
| non_ccRCC | 1.429 | ||||
| PDAC | -0.56 | ||||
| UCEC | 1.033 | ||||
| MYCBP2-Ser2787 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.819 | ||||
| COAD | -1.111 | ||||
| HGSC | |||||
| ccRCC | 0.083 | ||||
| GBM | 1.468 | ||||
| HNSC | -0.15 | ||||
| LUAD | -0.288 | ||||
| LUSC | 0.827 | ||||
| non_ccRCC | |||||
| PDAC | 0.582 | ||||
| UCEC | 0.408 | ||||
| MYCBP2-Ser2789 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.309 | ||||
| COAD | -0.459 | ||||
| HGSC | 2.583 | ||||
| ccRCC | -0.065 | ||||
| GBM | 0.597 | ||||
| HNSC | -0.522 | ||||
| LUAD | -0.459 | ||||
| LUSC | 0.225 | ||||
| non_ccRCC | -0.703 | ||||
| PDAC | 0.13 | ||||
| UCEC | -0.017 | ||||
| MYCBP2-Ser2812 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.702 | ||||
| HGSC | 0.155 | ||||
| ccRCC | -1.492 | ||||
| GBM | 0.248 | ||||
| HNSC | -0.018 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 1.939 | ||||
| PDAC | 0.397 | ||||
| UCEC | -0.527 | ||||
| MYCBP2-Ser2832 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2833 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.383 | ||||
| HGSC | -1.258 | ||||
| ccRCC | |||||
| GBM | 1.503 | ||||
| HNSC | 0.063 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.075 | ||||
| MYCBP2-Ser2839 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.8 | ||||
| HGSC | -1.121 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.321 | ||||
| MYCBP2-Ser2844 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2871 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.273 | ||||
| COAD | -0.949 | ||||
| HGSC | 2.278 | ||||
| ccRCC | -0.119 | ||||
| GBM | -0.564 | ||||
| HNSC | -0.402 | ||||
| LUAD | -0.032 | ||||
| LUSC | 1.144 | ||||
| non_ccRCC | 0.426 | ||||
| PDAC | 0.044 | ||||
| UCEC | -0.552 | ||||
| MYCBP2-Ser2873 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.453 | ||||
| HGSC | 1.478 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.305 | ||||
| LUAD | -0.719 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2911 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2920 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.286 | ||||
| COAD | -0.83 | ||||
| HGSC | 1.009 | ||||
| ccRCC | -0.555 | ||||
| GBM | 2.236 | ||||
| HNSC | -0.47 | ||||
| LUAD | |||||
| LUSC | -1.036 | ||||
| non_ccRCC | 0.58 | ||||
| PDAC | -0.503 | ||||
| UCEC | -0.144 | ||||
| MYCBP2-Ser2930 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser2985 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | -0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| MYCBP2-Ser342 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.865 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 1.095 | ||||
| LUAD | -0.229 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser3426 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser3478 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.205 | ||||
| HGSC | 1.554 | ||||
| ccRCC | |||||
| GBM | -0.615 | ||||
| HNSC | 1.15 | ||||
| LUAD | |||||
| LUSC | 0.034 | ||||
| non_ccRCC | -0.377 | ||||
| PDAC | -0.344 | ||||
| UCEC | -1.607 | ||||
| MYCBP2-Ser3505 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.528 | ||||
| COAD | 0.4 | ||||
| HGSC | 2.452 | ||||
| ccRCC | -0.586 | ||||
| GBM | -0.753 | ||||
| HNSC | 0.081 | ||||
| LUAD | 0.235 | ||||
| LUSC | 0.861 | ||||
| non_ccRCC | -0.296 | ||||
| PDAC | -0.953 | ||||
| UCEC | -0.915 | ||||
| MYCBP2-Ser3519 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.9 | ||||
| HGSC | 1.685 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.596 | ||||
| LUAD | -0.267 | ||||
| LUSC | -0.165 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.948 | ||||
| MYCBP2-Ser3931 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.456 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.891 | ||||
| GBM | -0.526 | ||||
| HNSC | -0.342 | ||||
| LUAD | 1.751 | ||||
| LUSC | 0.608 | ||||
| non_ccRCC | -1.652 | ||||
| PDAC | 0.312 | ||||
| UCEC | -0.585 | ||||
| MYCBP2-Ser3932 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.176 | ||||
| COAD | |||||
| HGSC | -1.779 | ||||
| ccRCC | 0.869 | ||||
| GBM | -0.515 | ||||
| HNSC | -0.088 | ||||
| LUAD | 1.536 | ||||
| LUSC | 0.649 | ||||
| non_ccRCC | -1.186 | ||||
| PDAC | 0.765 | ||||
| UCEC | -0.075 | ||||
| MYCBP2-Ser3944 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.635 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.518 | ||||
| LUSC | -1.153 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Ser899 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.776 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.802 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.503 | ||||
| LUSC | -0.444 | ||||
| non_ccRCC | |||||
| PDAC | 0.866 | ||||
| UCEC | 0.048 | ||||
| MYCBP2-Thr1625 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2058 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MYCBP2-Thr2344 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.636 | ||||
| GBM | |||||
| HNSC | 1.153 | ||||
| LUAD | -0.516 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2347 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr2683 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.322 | ||||
| HGSC | 1.836 | ||||
| ccRCC | 0.059 | ||||
| GBM | -0.907 | ||||
| HNSC | 0.32 | ||||
| LUAD | -0.883 | ||||
| LUSC | 0.739 | ||||
| non_ccRCC | 0.557 | ||||
| PDAC | 0.295 | ||||
| UCEC | -1.695 | ||||
| MYCBP2-Thr2880 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr3508 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Thr3921 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| MYCBP2-Thr3943 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Tyr3477 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCBP2-Tyr3484 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser352 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser355 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Ser361 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCN-Thr58 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Ser115 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.766 | ||||
| HGSC | 1.131 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.365 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Ser129 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.033 | ||||
| HGSC | 0.388 | ||||
| ccRCC | 0.202 | ||||
| GBM | |||||
| HNSC | -0.325 | ||||
| LUAD | -0.216 | ||||
| LUSC | -1.956 | ||||
| non_ccRCC | |||||
| PDAC | 0.874 | ||||
| UCEC | |||||
| MYCT1-Ser135 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.542 | ||||
| COAD | 0.75 | ||||
| HGSC | 0.574 | ||||
| ccRCC | 0.064 | ||||
| GBM | 1.358 | ||||
| HNSC | 1.25 | ||||
| LUAD | -0.087 | ||||
| LUSC | -0.849 | ||||
| non_ccRCC | -0.867 | ||||
| PDAC | -1.066 | ||||
| UCEC | -1.67 | ||||
| MYCT1-Ser138 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 1.696 | ||||
| ccRCC | -0.48 | ||||
| GBM | |||||
| HNSC | -0.812 | ||||
| LUAD | 0.734 | ||||
| LUSC | -1.023 | ||||
| non_ccRCC | -1.043 | ||||
| PDAC | 0.718 | ||||
| UCEC | 0.209 | ||||
| MYCT1-Ser141 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.047 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 1.444 | ||||
| LUSC | -0.582 | ||||
| non_ccRCC | -1.196 | ||||
| PDAC | |||||
| UCEC | 0.381 | ||||
| MYCT1-Ser149 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.23 | ||||
| COAD | -0.234 | ||||
| HGSC | 2.256 | ||||
| ccRCC | 0.036 | ||||
| GBM | 0.337 | ||||
| HNSC | -0.079 | ||||
| LUAD | -0.751 | ||||
| LUSC | -0.325 | ||||
| non_ccRCC | -0.535 | ||||
| PDAC | -0.527 | ||||
| UCEC | -1.409 | ||||
| MYCT1-Ser155 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.233 | ||||
| HGSC | 1.679 | ||||
| ccRCC | -0.048 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.429 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.969 | ||||
| MYCT1-Thr143 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.567 | ||||
| ccRCC | 0.377 | ||||
| GBM | |||||
| HNSC | 1.004 | ||||
| LUAD | -0.413 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.535 | ||||
| MYCT1-Thr219 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Tyr116 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MYCT1-Tyr126 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | 0.351 |
| GBM | |
| HNSC | -1.128 |
| LUAD | 0.778 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 58 | A | T-cell acute lymphoblastic leukemia | Phosphorylation | 32049046 |
| T | 58 | D | AIDS-related lymphoma | Phosphorylation | 17310999 |
| T | 58 | D | T-cell lymphoma | Phosphorylation | 17192266 |
| T | 58 | D | Papillary adenoma | Phosphorylation | 17192266 |
| T | 58 | D | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 17192266 |
| T | 58 | D | Islet cell carcinoma | Phosphorylation | 17192266 |
| T | 58 | D | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 17192266 |
| T | 58 | D | Breast cancer/tumor/carcinoma | Phosphorylation | 17192266 |
| T | 58 | D | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 17192266 |
| T | 58 | D | Triple-negative breast cancer | Phosphorylation | 33541412 |
| T | 58 | D | Cancer | Phosphorylation | 36639831 |
| T | 58 | D | Squamous cell carcinoma | Phosphorylation | 32895364 |
| T | 58 | D | Neuroblastoma | Phosphorylation | 37973789 |
| T | 58 | D | Breast cancer | Phosphorylation | 21808024 |
| T | 58 | D | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 10488335 |
| T | 58 | N | Cervical cancer/carcinoma | Phosphorylation | 15150404 |
| T | 58 | P | Burkitt lymphoma | Phosphorylation | 10713166 ; 10866684 |
| T | 58 | P | B-cell lymphoma | Phosphorylation | 10706881 |
| T | 58 | U | Papillary adenoma | Phosphorylation | 10360173 ; 17192266 |
| T | 58 | U | T-cell lymphoma | Phosphorylation | 10488335 ; 17192266 |
| T | 58 | U | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 12098700 ; 17192266 |
| T | 58 | U | Islet cell carcinoma | Phosphorylation | 12015982 ; 17192266 |
| T | 58 | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 15455033 ; 17192266 |
| T | 58 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 11175856 ; 17192266 |
| T | 58 | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 10488335 ; 17192266 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
